Is the pharmaceutical supply chain changing dramatically? Is China's opportunity coming?

Ask AI · How Will Global Logistics Disruptions Reshape the Perspective on Pharmaceutical Supply Chain Security?

Produced by | Miaotou APP

Author | Zhang Beibei

Editor | Ding Ping

Header Image | Visual China

The combined effects of rare earth restrictions and logistics disruptions caused by US-Iran conflicts are gradually exposing overlooked issues within the global pharmaceutical supply chain.

For many years, companies believed that as long as they minimized costs, kept inventories lean, and tightened delivery schedules, their supply chains were efficient; but now it’s clear that this model relies on continuous upstream raw material supply and smooth international logistics. If either of these conditions fails, even a seemingly smooth operation can quickly become fragile.

The most immediate impacts are on critical materials like rare earths and cross-border logistics. High-end equipment such as MRI and CT scanners, as well as cutting-edge nuclear medicines like Lu-177, depend heavily on key raw materials; radioactive drugs, clinical samples, and precision components also require efficient transportation. When raw material supplies tighten or logistics are hindered, pharmaceutical companies face not just rising costs but also the critical issues of timely production and delivery.

Particularly if logistics hubs in the Middle East fail, many problems will be amplified. Even if companies obtain export permits, they may not be able to ship goods smoothly; and even if transportation resumes later, the supply chain may not immediately return to normal, as high demand for raw materials, tight supplies, and extended delivery cycles could persist.

Therefore, this disruption is not just a short-term disturbance but a wake-up call for the market to recognize that pharmaceutical supply chains must prioritize not only efficiency but also security and controllability.

This suggests that the pharmaceutical supply chain may undergo a new wave of restructuring. Those who can address gaps in key materials, manufacturing capacity, and supply stability are more likely to gain an advantage in the next phase. What role will China’s pharmaceutical industry play in this restructuring? Where will future development focus, and what transformation paths lie ahead? These are the questions worth exploring further.

Supply Chains Are No Longer Just About Efficiency

For many years, the global pharmaceutical industry followed a simple logic: production capacity was allocated to wherever costs were lowest and efficiency was highest. Raw materials, manufacturing, R&D, logistics—each could be broken down into finer segments, and costs could be pushed down as much as possible. When global trade was smooth, this model worked well.

But recent years have changed that. Geopolitical conflicts, trade frictions, and logistics disruptions have revealed that the pharmaceutical industry cannot focus solely on efficiency; safety is equally important. The small savings achieved during normal times can be quickly wiped out when supply is interrupted, shipping is halted, or supply chains break.

Now, the US, Europe, and Japan are all working on one key strategy: trying to bring critical drugs, raw materials, and manufacturing capabilities back under their control as much as possible.

The US is promoting domestic production of some essential raw materials, Europe is accelerating the construction of advanced therapy manufacturing bases, and Japan is subsidizing the domestic production of sterile injectables and mRNA vaccines. Essentially, all are addressing the same core issue—shifting away from a supply chain that prioritized “cheap and fast” toward one that emphasizes “stability and controllability.”

From this perspective, restrictions on rare earths and disruptions in Middle Eastern logistics are not isolated incidents. They simply expose a deeper problem: the previous global pharmaceutical supply chain strategy of cost optimization alone is increasingly inadequate.

In this context, China may not just be a passive responder but could become even more critical.

The reason is straightforward. China’s pharmaceutical industry is characterized not only by large capacity but also by a comprehensive supply chain.

From basic chemical raw materials, intermediates, and active pharmaceutical ingredients (APIs) to formulations, medical devices, packaging materials, and from CRO/CDMO services to distribution and end markets—China has the capacity to supply at scale across these segments. While other countries may excel in certain areas, few can integrate so many segments into a cohesive system like China.

The value of this capability may not be immediately apparent when the supply chain is stable, but as external conditions become more volatile, its importance will grow. Ultimately, the market’s competition is not just about which segment is strongest but about who can keep the entire chain as stable as possible.

For example, China’s long-standing position in API production is not only due to cost advantages but also because of comprehensive supporting infrastructure, full capacity, and quick responsiveness. Even when raw material prices rise or logistics fluctuate externally, China’s extensive chemical industry base and diverse raw material sources often provide stronger buffers.

On the innovation front, progress is also evident. While China was once mainly seen as a manufacturing and contract production hub, recent years have seen a significant rise in innovative drug R&D, licensing, and pipeline development. In essence, China’s pharmaceutical industry is increasingly involved in upstream activities—deciding what drugs to develop, how to produce them, and where to sell.

Looking ahead, China’s role in the global pharmaceutical supply chain may shift from merely a “cost center” or “manufacturing workshop” to a more central position:

• Providing stable manufacturing and supply capabilities
• Gradually enhancing R&D, translation, and commercialization strengths

Those who can both ensure supply and innovate will naturally gain more influence.

Policy is also aligning with this trend

If industry changes are driven by external pressures, policy shifts are proactive responses.

This year’s two sessions elevated biopharmaceuticals to a “new pillar industry,” signaling a clear message: pharmaceuticals are not just a livelihood sector but also a key component of growth and competitiveness.

This repositioning is significant. Once placed in the “pillar industry” category, the support will extend beyond rhetoric to include resource allocation, policy incentives, capital, and talent. In other words, the government’s expectations for the pharmaceutical sector are no longer limited to “supply security” but also include “upgrading,” “breakthroughs,” and “enhanced international competitiveness.”

Focusing on the supply chain, two areas are particularly critical: innovative drugs and APIs.

One represents upward technological advancement; the other provides foundational support.

(1) Innovative Drugs: Not Just About Marketability

Policy support for innovative drugs has become increasingly comprehensive.

On the regulatory side, efforts are underway to streamline access, such as adjusting hospital drug evaluation and reimbursement policies; on the payment side, new avenues are opening for innovative drugs, like commercial insurance, which addresses the core concern: can companies profit from their innovations?

Previously, many companies focused on entering the national insurance list, as without reimbursement, sales would be limited; but in the future, the logic may shift. Insurance is now seen as a baseline, while truly valuable, clinically differentiated innovative drugs will rely more on commercial insurance, out-of-pocket payments, and multi-layered payment systems to generate higher returns.

This will directly influence R&D priorities.

In the future, competition will shift from who can develop “just-eligible-for-reimbursement” drugs to who can create truly effective, differentiated products that payers are willing to invest in. This change is positive for the industry, as it encourages moving away from low-level repetition toward genuine innovation.

Additionally, “AI +” applications in pharma—particularly AI-driven drug discovery—are gaining attention. This isn’t just hype; AI has the potential to shorten R&D cycles and reduce trial-and-error costs. For China, leveraging data, computing power, and engineering capabilities in conjunction with pharmaceutical R&D could push the innovation pipeline forward.

Thus, innovative drugs are not just a high-growth segment but a driver for the entire industry’s upward movement. Once successful, they will also boost upstream tools, reagents, equipment, and research platforms.

(2) APIs: Not Just “Low-Cost Manufacturing”

The other key area is APIs.

Historically, APIs have been viewed as “low-margin, labor-intensive” products, relying on cost, capacity, environmental compliance, and scale. But in today’s environment of repeated global supply chain disruptions, their importance is being re-evaluated.

APIs are the foundation of the entire pharmaceutical industry.

Without them, both generic and innovative drugs cannot operate. Companies that master stable, scalable, and reliable API supply will have a stronger, irreplaceable position in the industry.

China’s advantages in this area are unlikely to be fully replaced in the short term.

It’s not just because of large production volume but also because many categories have developed complete supporting infrastructure and scale advantages. While Western countries have been advocating localization and reducing dependence, relocating these capacities involves real issues—cost, lead time, environmental standards, talent, and supporting industries—making it difficult to simply “move back.”

More importantly, China is no longer just producing low-end bulk APIs. It has gained a stronger foothold in high-end specialty APIs, patent-protected formulations, and advanced segments like CDMO. This shift indicates a move from “large volume, low price” to “both volume and quality.”

Note: “Patent drug support” mainly refers to contract manufacturing services providing APIs and intermediates for original drug developers, including simple production (CMO) and more complex, technologically intensive services. CDMO models that support patented drugs must include strong process R&D and technological innovation capabilities to optimize processes, reduce costs, and solve technical challenges.

Therefore, the API segment should not be viewed merely as maintaining the status quo.

It is the foundation for China’s pharmaceutical industry to continue climbing upward.

A stable foundation means broader development space for the entire pharmaceutical industry—from R&D to manufacturing.

In conclusion

The current changes in the pharmaceutical industry are not simply summarized as “resilience era has arrived.” More directly, it’s about shifting from a focus on who is cheaper and faster to who is more stable, comprehensive, and capable of continuous innovation.

Within this framework, China has the opportunity to reposition itself.

On one hand, a complete industry chain enhances China’s role in “supply security”; on the other, advancing innovation capabilities allows China to move beyond order-taking and manufacturing, participating in higher-value segments.

Policy emphasis on innovative drugs and APIs reflects this approach: one aims to break through upward, the other to solidify the foundation. If both can be established, China’s role in the global supply chain restructuring will not be just “following changes,” but actively leading.

Disclaimer: The content of this article is for reference only. The information or opinions expressed do not constitute investment advice. Readers should exercise caution when making investment decisions.

End